Eton Q2 Revenue Jumps 99% to $37.6M; FY Guide Raised to $145M
Eton Pharmaceuticals grew Q2 2026 revenue 99% to $37.6 million on rare disease and pediatric endocrinology strength, relaunched HEMANGEOL, and licensed late-stage ASN-001. Bio investors should watch margin guidance and pipeline execution.
Source: manilatimes.net · prnewswire.com